Navigation Links
SeraCare Acknowledges Receipt of Unsolicited Proposal from MSMB Capital
Date:6/23/2011

MILFORD, Mass., June 23, 2011 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today acknowledged the receipt of an unsolicited offer from MSMB Capital proposing to purchase all of the outstanding shares of SeraCare for $4.25 per share. It is anticipated that the SeraCare Board of Directors will review the proposal in due course.

(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO)

About SeraCare Life Sciences, Inc.:

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these assumptions will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, prolonged impairment of sales from changes in our sales organization, potential difficulties hiring sales personnel with the desired qualifications, revenue shortfalls arising from customer transitions to new products, unpredictability in large customer orders, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.

Contacts:
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
508-244-6400

Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060


'/>"/>
SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SeraCare Life Sciences Announces Renewal of National Institutes of Health Contract to Support Research
2. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
3. Axis-Shield Acknowledges World Diabetes Day and Provides an Update on its Growing Diabetes Franchise in Emerging Markets
4. Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution
5. InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA
6. Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
9. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
10. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
11. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... Sept. 5, 2017  Xyntek Inc. has announced another milestone in their continued ... office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, ... ... regionally. ...
(Date:9/5/2017)... Sept. 5, 2017  Just 18 months after its ... pleased to announce the appointment of three new senior ... , Dominic Jones-Phillips and James Wright ... Tammy Wynne ... market access writers. She has over ten years, experience ...
(Date:9/1/2017)... , Sept. 1, 2017 Michael ... Solutions, Inc , highlights opportunities for growth in his ... report that Marlin Equity is seeking a buyer for ... annual award-winning 22-year-old healthcare solutions Value Added Reseller and ... "As the healthcare market ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that ... and commercial support services market) has entered into an agreement on September 1, ... , The PGSD is the first private Dental School to launch an online, ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time since ... been receiving positive feedback from customers trying the product for the first time, and ... Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at risk ...
(Date:9/20/2017)... ... 2017 , ... Medicare doesn’t have the authority to negotiate ... their prescription drugs, according to a new comparison of drug plans by ... there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare policy ...
(Date:9/20/2017)... ... September 20, 2017 , ... “RECYCLED Ezekiel's ... Ezekiel's Plan for Freedom from ADDICTION” is the creation of published author, Bill ... of addiction and homeless services, including more than a decade of addiction to ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is a fascinating depiction ... move the readers one step closer to God. “Psalms of Humidity” is the creation ... that have been made within his life are the very same things that have ...
Breaking Medicine News(10 mins):